SAN DIEGO--(BUSINESS WIRE)--
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and
manufacturer of the only touchscreen insulin pumps available in the
United States, today announced the issuance of U.S. Patent No.
9,715,327 titled "Preventing Inadvertent Changes in Ambulatory
Medical Devices". The patent relates to important safety features
for the prevention of inadvertent changes in touchscreen enabled
ambulatory infusion pumps, including insulin pumps. The touchscreen may
be on the pump itself or be in wireless communication with a pump.
"We are the first and only company to receive FDA approval of an insulin
pump with a touchscreen. This patent significantly strengthens our
intellectual property position surrounding Tandem's user interface and
the implementation of important features in other ambulatory infusion
pumps that utilize touchscreen control," said Kim Blickenstaff,
President and Chief Executive Officer of Tandem Diabetes Care. "This new
patent validates the novel solutions we developed to give users the
security of operating a life-sustaining medical device using a
touchscreen and protects the creative solutions developed at Tandem."
The user interface for the t:slim, t:slim X2, t:flex and t:slim G4
Insulin Pumps were developed based on information and feedback collected
from thousands of interviews, focus groups and online surveys to
understand what people with diabetes, their caregivers and healthcare
providers wanted in order to improve diabetes therapy management. The
Company also utilized human factors research in its development process
so that users can more successfully operate their insulin pump in its
intended environment.
U.S. Patent No. 9,715,327 is scheduled to expire in 2033. The
Company has a related U.S. continuation application on file, as well as
a pending application in Europe.
Tandem Diabetes Care now has 55 issued U.S. patents and 51 pending U.S.
patent applications. In addition, the Company has, and is seeking,
patent protection for proprietary technologies in other countries
throughout the world.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company with an innovative, user-centric and
integrated approach to the design, development and commercialization of
products for people with diabetes who use insulin. The Company
manufactures and sells the t:slim X2™ Insulin Pump, the slimmest and
smallest durable insulin pump currently on the market, the t:flex®
Insulin Pump, the first pump designed for people with greater insulin
requirements, and the t:slim G4™ Insulin Pump, the first continuous
glucose monitoring-enabled pump with touch-screen simplicity. Tandem is
based in San Diego, California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2,
#tslimG4, #tflex, #tconnect, and $TNDM.
Follow Tandem Diabetes Care
on Facebook at www.facebook.com/TandemDiabetes.
Follow
Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.
Tandem Diabetes Care, t:connect and t:flex are registered trademarks,
and t:slim X2 and t:slim G4 are trademarks of Tandem Diabetes Care, Inc.
All other trademarks are the property of their respective owners.
Forward Looking Statement
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, that
concern matters that involve risks and uncertainties that could cause
actual results to differ materially from those anticipated or projected
in the forward-looking statements. These forward-looking statements
relate to, among other things the scope and enforceability of the
company's intellectual property, including the expected expiration of
the 9,715,327 patent. Many factors could cause the company's actual
results, performance or achievements to be materially different from any
future results, performance or achievements that may be expressed or
implied by such forward-looking statements, including without
limitation, those listed under the heading "Risk Factors" in the
company's most recent Annual Report on Form 10-K, Quarterly Report on
Form 10-Q and other documents that Tandem files with the Securities and
Exchange Commission. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of
this release. Tandem undertakes no obligation to update or review any
forward-looking statement in this press release because of new
information, future events or other factors.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170808005337/en/
Tandem Diabetes Care, Inc.
Media Contact:
Steve
Sabicer, 714-907-6264
ssabicer@thesabicergroup.com
or
Investor
Contact:
Susan Morrison,858-366-6900 x7005
smorrison@tandemdiabetes.com
Source: Tandem Diabetes Care, Inc.
News Provided by Acquire Media
